Lynk Pharmaceuticals
Explore the latest insights on Lynk Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lynk Pharmaceuticals’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Edding Genor Secures Dual NMPA IND Approvals for GB268 – PD‑1/CTLA‑4/VEGF Trispecific Antibody Advances into NSCLC and First‑Line Biliary Tract Cancer Trial
Edding Genor (HKG: 6998) announced that China's National Medical Products Administration (NMPA) has approved two investigational new drug (IND) applications for GB268, the company's highly differentiated PD‑1/CTLA‑4/VEGF trispecific antibody: a…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
